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Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo
Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist
of information to include in publications describing in vivo experiments to enable others to scrutinise the work ade-
quately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of
endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the
anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here,
we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in
practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the “ARRIVE Essential
10,” which constitutes the minimum requirement, and the “Recommended Set,” which describes the research context.
This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation.
This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We
have also developed the accompanying Explanation and Elaboration document, which serves (1) to explain the rationale
behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through
these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour
and transparency of the scientific process and thus reproducibility.
This article was originally published in Plos Biology,
https://doi.org/10.1371/journal.pbio.3000410, under a
CC-BY license.
Abbreviations
ARRIVE, Animal Research: Reporting of In Vivo
Experiments; FAIR, Findable, Accessible,
Interoperable, Reusable; E&E, Explanation and
Elaboration; MDAR, Materials, Design, Analysis
and Reporting; NIH, National Institutes of Health;
Why good reporting is important
In recent years, concerns about the reproducibility of
research findings have been raised by scientists, fun-
ders, research users, and policy makers.1,2 Factors
that contribute to poor reproducibility include flawed
study design and analysis, variability and inadequate
validation of reagents and other biological materials,
insufficient reporting of methodology and results, and
barriers to accessing data3. The bioscience community
has introduced a range of initiatives to address the
problem, from open access and open practices to
enable the scrutiny of all aspects of the research4,5
through to study preregistration to shift the focus
towards robust methods rather than the novelty of
the results,6,7 as well as resources to improve experi-
mental design and statistical analysis.8–10
Transparent reporting of research methods and find-
ings is an essential component of reproducibility.
Without this, the methodological rigour of the studies
cannot be adequately scrutinised, the reliability of the
findings cannot be assessed, and the work cannot be
repeated or built upon by others. Despite the
development of specific reporting guidelines for pre-
clinical and clinical research, evidence suggests that sci-
entific publications often lack key information and that
there continues to be considerable scope for improve-
ment.11–18 Animal research is a good case in point,
where poor reporting impacts on the development of
therapeutics and irreproducible findings can spawn an
entire field of research, or trigger clinical studies, sub-
jecting patients to interventions unlikely to be
effective.2,19,20
In an attempt to improve the reporting of animal
research, the ARRIVE guidelines (Animal Research:
Reporting of In Vivo Experiments) were published in
2010. The guidelines consist of a checklist of the items
that should be included in any manuscript that reports
in vivo experiments, to ensure a comprehensive and
transparent description.21–30 They apply to any area
of research using live animal species and are especially
pertinent to describe comparative research in the labo-
ratory or other formal test setting. The guidelines are
also relevant in a wider context, for example, for obser-
vational research, studies conducted in the field, and
where animal tissues are used. In the 10 years since
publication, the ARRIVE guidelines have been
endorsed by more than a thousand journals from
across the life sciences. Endorsement typically includes
advocating their use in guidance to authors and
reviewers. However, despite this level of support,
recent studies have shown that important information
as set out in the ARRIVE guidelines is still missing
from most publications sampled. This includes details
on randomisation (reported in only 30%–40% of pub-
lications), blinding (reported in only approximately
20% of publications), sample size justification
(reported in less than 10% of publications), and
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animal characteristics (all basic characteristics reported
in less than 10% of publications).11,31,32
Evidence suggests that 2 main factors limit the
impact of the ARRIVE guidelines. The first is the
extent to which editorial and journal staff are actively
involved in enforcing reporting standards. This is illus-
trated by a randomised controlled trial at PLOS ONE,
designed to test the effect of requesting a completed
ARRIVE checklist in the manuscript submission pro-
cess. This single editorial intervention, which did not
include further verification from journal staff, failed to
improve the disclosure of information in published
papers.34 In contrast, other studies using shorter check-
lists (primarily focused on experimental design) with
more editorial follow-up have shown a marked
improvement in the nature and detail of the informa-
tion included in publications.34–36 It is likely that the
level of resource required from journals and editors
currently prohibits the implementation of all the
items of the ARRIVE guidelines.
The second issue is that researchers and other indi-
viduals and organisations responsible for the integrity
of the research process are not sufficiently aware of the
consequences of incomplete reporting. There is some
evidence that awareness of ARRIVE is linked to the
use of more rigorous experimental design standards;38
however, researchers are often unfamiliar with the
much larger systemic bias in the publication of research
and in the reliability of certain findings and even of
entire fields.33,38–40 This lack of understanding affects
how experiments are designed and grant proposals pre-
pared, how animals are used and data recorded in the
laboratory, and how manuscripts are written by
authors or assessed by journal staff, editors, and
reviewers.
Approval for experiments involving animals is gen-
erally based on a harm–benefit analysis, weighing the
harms to the animals involved against the benefits of
the research to society. If the research is not reported in
enough detail, even when conducted rigorously, the
benefits may not be realised, and the harm–benefit
analysis and public trust in the research are under-
mined.41 As a community, we must do better to
ensure that, where animals are used, the research is
both well designed and analysed as well as transparent-
ly reported. Here, we introduce the revised ARRIVE
guidelines, referred to as ARRIVE 2.0. The informa-
tion included has been updated, extended, and reorgan-
ised to facilitate the use of the guidelines, helping to
ensure that researchers, editors, and reviewers—as well
as other relevant journal staff—are better equipped to
improve the rigour and reproducibility of animal
research.
Introducing ARRIVE 2.0
In ARRIVE 2.0, we have improved the clarity of the
guidelines, prioritised the items, added new informa-
tion, and generated the accompanying Explanation
and Elaboration (E&E) document to provide context
and rationale for each item42 (also available at https://
www.arriveguidelines.org). New additions comprise
inclusion and exclusion criteria, which are a key
aspect of data handling and prevent the ad hoc exclu-
sion of data;43 protocol registration, a recently emerged
approach that promotes scientific rigour and encour-
ages researchers to carefully consider the experimental
design and analysis plan before any data are collect-
ed;44 and data access, in line with the FAIR Data
Principles (Findable, Accessible, Interoperable,
Reusable).45 S1 Table summarises the changes.
The most significant departure from the original
guidelines is the classification of items into 2 prioritised
groups, as shown in Tables 1 and 2. There is no ranking
of the items within each group. The first group is the
“ARRIVE Essential 10,” which describes information
that is the basic minimum to include in a manuscript,
as without this information, reviewers and readers
cannot confidently assess the reliability of the findings
presented. It includes details on the study design, the
sample size, measures to reduce subjective bias, out-
come measures, statistical methods, the animals, exper-
imental procedures, and results. The second group,
referred to as the “Recommended Set,” adds context
to the study described. This includes the ethical state-
ment, declaration of interest, protocol registration, and
data access, as well as more detailed information on the
methodology such as animal housing, husbandry, care,
and monitoring. Items on the abstract, background,
objectives, interpretation, and generalisability also
describe what to include in the more narrative parts
of a manuscript.
Revising the guidelines has been an extensive and
collaborative effort, with input from the scientific com-
munity carefully built into the process. The revision of
the ARRIVE guidelines has been undertaken by an
international working group—the authors of this pub-
lication—with expertise from across the life sciences
community, including funders, journal editors, statisti-
cians, methodologists, and researchers from academia
and industry. We used a Delphi exercise46 with external
stakeholders to maximise diversity in fields of expertise
and geographical location, with experts from 19 coun-
tries providing feedback on each item, suggesting new
items, and ranking items according to their relative
importance for assessing the reliability of research find-
ings. This ranking resulted in the prioritisation of the
items of the guidelines into the 2 sets. Demographics of
the Delphi panel and full methods and results are
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presented in Supporting Information S1 Delphi and S1
Data. Following their publication on BioRxiv, the
revised guidelines and the E&E were also road tested
with researchers preparing manuscripts describing in
vivo studies, to ensure that these documents were
well understood and useful to the intended users.
This study is presented in Supporting Information S1
Road Testing and S2 Data.
While reporting animal research in adherence to all
21 items of ARRIVE 2.0 represents best practice, the
classification of the items into 2 groups is intended to
facilitate the improved reporting of animal research by
Table 1. ARRIVE Essential 10.
ARRIVE Essential 10
Study design 1 For each experiment, provide brief details of study design including:
a. The groups being compared, including control groups. If no control group has been
used, the rationale should be stated.
b. The experimental unit (e.g., a single animal, litter, or cage of animals).
Sample size 2 a. Specify the exact number of experimental units allocated to each group, and the total
number in each experiment. Also indicate the total number of animals used.
b. Explain how the sample size was decided. Provide details of any a priori sample size
calculation, if done.
Inclusion and
exclusion criteria
3 a. Describe any criteria used for including and excluding animals (or experimental units)
during the experiment, and data points during the analysis. Specify if these criteria were
established a priori. If no criteria were set, state this explicitly.
b. For each experimental group, report any animals, experimental units, or data points not
included in the analysis and explain why. If there were no exclusions, state so.
c. For each analysis, report the exact value of n in each experimental group.
Randomisation 4 a. State whether randomisation was used to allocate experimental units to control and
treatment groups. If done, provide the method used to generate the randomisation
sequence.
b. Describe the strategy used to minimise potential confounders such as the order of
treatments and measurements, or animal/cage location. If confounders were not
controlled, state this explicitly.
Blinding 5 Describe who was aware of the group allocation at the different stages of the experiment
(during the allocation, the conduct of the experiment, the outcome assessment, and
the data analysis).
Outcome measures 6 a. Clearly define all outcome measures assessed (e.g., cell death, molecular markers, or
behavioural changes).
b. For hypothesis-testing studies, specify the primary outcome measure, i.e., the outcome
measure that was used to determine the sample size.
Statistical methods 7 a. Provide details of the statistical methods used for each analysis, including software used.
b. Describe any methods used to assess whether the data met the assumptions of the
statistical approach, and what was done if the assumptions were not met.
Experimental animals 8 a. Provide species-appropriate details of the animals used, including species, strain and
substrain, sex, age or developmental stage, and, if relevant, weight.
b. Provide further relevant information on the provenance of animals, health/immune
status, genetic modification status, genotype, and any previous procedures.
Experimental procedures 9 For each experimental group, including controls, describe the procedures in enough detail
to allow others to replicate them, including:
a. What was done, how it was done, and what was used.
b. When and how often.
c. Where (including detail of any acclimatisation periods).
d. Why (provide rationale for procedures).
Results 10 For each experiment conducted, including independent replications, report:
a. Summary/descriptive statistics for each experimental group, with a measure of vari-
ability where applicable (e.g., mean and SD, or median and range).
b. If applicable, the effect size with a confidence interval.
Explanations and examples for items 1 to 10 are available in the Explanation and Elaboration document42 and on the website at https://www.
arriveguidelines.org.
Abbreviations: ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments).
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allowing an initial focus on the most critical issues. This
better allows journal staff, editors, and reviewers to
verify that the items have been adequately reported in
manuscripts. The first step should be to ensure compli-
ance with the ARRIVE Essential 10 as a minimum
requirement. Items from the Recommended Set can
then be added over time and in line with specific edi-
torial policies until all the items are routinely reported
in all manuscripts. ARRIVE 2.0 are fully compatible
with and complementary to other guidelines that have
been published in recent years. By providing a compre-
hensive set of recommendations that are specifically
tailored to the description of in vivo research, they
help authors reporting animal experiments adhere to
the National Institutes of Health (NIH) standards43
and the minimum standards framework and
checklist (Materials, Design, Analysis and Reporting
[MDAR]).47 The revised guidelines are also in line
with many journals’ policies and will assist authors in
complying with information requirements on the ethi-
cal review of the research,48,49 data presentation and
access,50–52 statistical methods,51,52 and conflicts of
interest.53,54
Although the guidelines are written with researchers
and journal editorial policies in mind, it is important to
stress that researchers alone should not have to carry
the responsibility for transparent reporting. Funders,
institutions, and publishers’ endorsement of ARRIVE
has been instrumental in raising awareness to date; they
now have a key role to play in building capacity and
Table 2. ARRIVE Recommended Set.
Recommended Set
Abstract 11 Provide an accurate summary of the research objectives, animal species, strain and sex,
key methods, principal findings, and study conclusions.
Background 12 a. Include sufficient scientific background to understand the rationale and context for the
study, and explain the experimental approach.
b. Explain how the animal species and model used address the scientific objectives and,
where appropriate, the relevance to human biology.
Objectives 13 Clearly describe the research question, research objectives and, where appropriate,
specific hypotheses being tested.
Ethical statement 14 Provide the name of the ethical review committee or equivalent that has approved the use
of animals in this study, and any relevant licence or protocol numbers (if applicable). If
ethical approval was not sought or granted, provide a justification.
Housing and husbandry 15 Provide details of housing and husbandry conditions, including any environmental
enrichment.
Animal care and monitoring 16 a. Describe any interventions or steps taken in the experimental protocols to reduce pain,
suffering, and distress.
b. Report any expected or unexpected adverse events.
c. Describe the humane endpoints established for the study, the signs that were moni-
tored, and the frequency of monitoring. If the study did not have humane endpoints,
state this.
Interpretation/scientific
implications
17 a. Interpret the results, taking into account the study objectives and hypotheses, current
theory, and other relevant studies in the literature.
b. Comment on the study limitations, including potential sources of bias, limitations of the
animal model, and imprecision associated with the results.
Generalisability/translation 18 Comment on whether, and how, the findings of this study are likely to generalise to other
species or experimental conditions, including any relevance to human biology (where
appropriate).
Protocol registration 19 Provide a statement indicating whether a protocol (including the research question, key
design features, and analysis plan) was prepared before the study, and if and where this
protocol was registered.
Data access 20 Provide a statement describing if and where study data are available.
Declaration of interests 21 a. Declare any potential conflicts of interest, including financial and nonfinancial. If none
exist, this should be stated.
b. List all funding sources (including grant identifier) and the role of the funder(s) in the
design, analysis, and reporting of the study.
Together with the Essential 10, the Recommended Set represents best reporting practice. Explanations and examples for items 11 to 21 are available in
the Explanation and Elaboration document42 and on the website https://www.arriveguidelines.org.
Abbreviations: ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments)
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championing the behavioural changes required to
improve reporting practices. This includes embedding
ARRIVE 2.0 in appropriate training, workflows, and
processes to support researchers in their different roles.
While the primary focus of the guidelines has been on
the reporting of animal studies, ARRIVE also has
other applications earlier in the research process,
including in the planning and design of in vivo experi-
ments. For example, requesting a description of the
study design in line with the guidelines in funding or
ethical review applications ensures that steps to mini-
mise experimental bias are considered at the beginning
of the research cycle.55
Conclusion
Transparent reporting is clearly essential if animal
studies are to add to the knowledge base and inform
future research, policy, and clinical practice. ARRIVE
2.0 prioritises the reporting of information related to
study reliability. This enables research users to assess
how much weight to ascribe to the findings and, in
parallel, promotes the use of rigorous methodology in
the planning and conduct of in vivo experiments,37 thus
increasing the likelihood that the findings are reliable
and, ultimately, reproducible.
The intention of ARRIVE 2.0 is not to supersede
individual journal requirements but to promote a
harmonised approach across journals to ensure that
all manuscripts contain the essential information
needed to appraise the research. Journals usually
share a common objective of improving the methodo-
logical rigour and reproducibility of the research they
publish, but different journals emphasise different
pieces of information.56–58 Here, we propose an
expert consensus on information to prioritise. This
will provide clarity for authors, facilitate transfer of
manuscripts between journals, and accelerate an
improvement of reporting standards.
Concentrating the efforts of the research and pub-
lishing communities on the ARRIVE Essential 10 items
provides a manageable approach to evaluate reporting
quality efficiently and assess the effect of interventions
and policies designed to improve the reporting of
animal experiments. It provides a starting point for
the development of operationalised checklists to
assess reporting, ultimately leading to the build of
automated or semi-automated artificial intelligence
tools that can detect missing information rapidly.59
Improving reporting is a collaborative endeavour,
and concerted effort from the biomedical research com-
munity is required to ensure maximum impact. We wel-
come collaboration with other groups operating in this
area, as well as feedback on ARRIVE 2.0 and our
implementation strategy.
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